Loading...
Loading...
SURF| Name | Value |
|---|---|
| Revenues | 30.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 30.0M |
| Operating Expense | 23.2M |
| Operating I/L | 6.8M |
| Other Income/Expense | 0.0M |
| Interest Income | 0.0M |
| Pretax | 6.2M |
| Income Tax Expense | 0.7M |
| Net Income/Loss | 6.2M |
Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing cancer therapies. The company's revenue is generated through the development and commercialization of various antibodies, including NZV930 and SRF617 targeting adenosine production, SRF388 targeting interleukin 27, GSK4381562 targeting CD112R, and SRF114 targeting CCR8. Surface Oncology, Inc. has license agreements with GlaxoSmithKline and Vaccinex, Inc. to develop, manufacture, and commercialize specific antibodies. These partnerships contribute to the company's revenue stream as it progresses its antibody therapies through clinical development and potential commercialization.
